NEW YORK (GenomeWeb News) – RNAi research services company Cenix BioScience said today it has signed an agreement to help CellCentric validate oncology drug candidates.
Dresden, Germany-based Cenix said it will combine high-throughput applications of RNAi-based gene silencing with high-content phenotypic analyses in cultured human cells to provide in vitro validation of several of CellCentric’s drug candidates.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.